Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients With Non-Gorlin High Frequency BCC
Conditions
Interventions
Patidegib Topical Gel, 2%
Patidegib Topical Gel, Vehicle
Locations
14
United States
Axiom Research, LLC
Apple Valley, California, United States
Axiom Research, LLC
Colton, California, United States
Center for Dermatology Clinical Research, Inc.
Fremont, California, United States
Dermatology Research Associates
Los Angeles, California, United States
The Dermatology Center of Newport
Newport Beach, California, United States
Palm Beach Dermatology Research
Delray Beach, Florida, United States
Start Date
December 20, 2019
Primary Completion Date
April 23, 2021
Completion Date
April 23, 2021
Last Updated
May 31, 2023
NCT00397384
NCT00031681
Lead Sponsor
Sol-Gel Technologies, Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions